Stock Analysis on Net

Illumina Inc. (NASDAQ:ILMN)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 5, 2021.

Economic Value Added (EVA)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Illumina Inc., economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2020 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The period under review demonstrates fluctuating economic profit performance. Net operating profit after taxes (NOPAT) generally increased from 2016 to 2019, but experienced a substantial decline in 2020. Simultaneously, the cost of capital exhibited a gradual upward trend throughout the period. Invested capital increased consistently until 2020, where it showed a slight decrease.

Economic Profit Trend
Economic profit initially showed strong growth, rising from US$28 million in 2016 to US$202 million in 2017, and further to US$200 million in 2019. However, in 2020, economic profit turned negative, reaching US$ -163 million. This reversal indicates that the return generated from invested capital was insufficient to cover the cost of that capital in the most recent year.
NOPAT and Cost of Capital Relationship
While NOPAT increased between 2016 and 2019, the concurrent rise in the cost of capital suggests increasing funding expenses or perceived risk. The significant drop in NOPAT in 2020, coupled with the highest cost of capital during the period (15.39%), directly contributed to the negative economic profit observed that year. The increasing cost of capital appears to be outpacing the ability to generate profits.
Invested Capital Impact
Invested capital grew steadily from US$2,874 million in 2016 to US$4,997 million in 2019. The slight decrease to US$4,907 million in 2020 did not offset the impact of declining NOPAT and rising cost of capital. The larger capital base in recent years likely amplified the negative effect of insufficient returns, as a greater amount of capital was deployed at a time when profitability was decreasing.

Overall, the analysis reveals a shift from positive economic profit generation to economic loss in 2020. This outcome is attributable to a combination of declining operational profitability and a consistently increasing cost of capital, despite substantial investment.


Net Operating Profit after Taxes (NOPAT)

Illumina Inc., NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Net income attributable to Illumina stockholders
Deferred income tax expense (benefit)1
Increase (decrease) in allowance for doubtful accounts2
Increase (decrease) in reserve for product warranties3
Increase (decrease) in equity equivalents4
Interest expense
Interest expense, operating lease liability5
Adjusted interest expense
Tax benefit of interest expense6
Adjusted interest expense, after taxes7
(Gain) loss on marketable securities
Interest income
Investment income, before taxes
Tax expense (benefit) of investment income8
Investment income, after taxes9
Net income (loss) attributable to noncontrolling interest
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in allowance for doubtful accounts.

3 Addition of increase (decrease) in reserve for product warranties.

4 Addition of increase (decrease) in equity equivalents to net income attributable to Illumina stockholders.

5 2020 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

6 2020 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

7 Addition of after taxes interest expense to net income attributable to Illumina stockholders.

8 2020 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

9 Elimination of after taxes investment income.


Net Income Attributable to Illumina Stockholders
The net income demonstrated an overall upward trend from 2016 to 2019, starting at 463 million US dollars in 2016 and reaching a peak of 1002 million US dollars in 2019. This represents a substantial growth over the four-year period. However, in 2020, there was a notable decline to 656 million US dollars, which indicates a reversal of the previous growth trend.
Net Operating Profit After Taxes (NOPAT)
NOPAT followed a similar pattern to net income, increasing consistently from 453 million US dollars in 2016 to 957 million US dollars in 2019. This increase reflects improving operational efficiency and profitability. However, in 2020, NOPAT decreased to 593 million US dollars, signaling a significant downturn in operating profitability in that year.
Overall Observations
Both net income and NOPAT showed strong positive growth through 2019, indicating solid financial performance and effective management of operational costs and taxes. The decline observed in 2020 suggests that external factors or internal challenges may have adversely affected profitability. The 2020 results warrant further investigation to identify specific causes and to assess the sustainability of future earnings.

Cash Operating Taxes

Illumina Inc., cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Provision for income taxes
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).


The financial data reveals the trends in tax-related expenses over five fiscal years ending from 2016 to 2020. Both the provision for income taxes and cash operating taxes have exhibited fluctuations throughout this period.

Provision for Income Taxes
This item showed a significant increase from $133 million in 2016 to a peak of $365 million in 2017. Subsequently, it decreased sharply to $112 million in 2018 and remained relatively stable in 2019 with a slight increase to $128 million. In 2020, there was a notable rise again to $200 million.
Cash Operating Taxes
Cash operating taxes also followed a somewhat similar pattern, increasing from $140 million in 2016 to $344 million in 2017. After 2017, there was a decline to $133 million in 2018, followed by a further decrease to $114 million in 2019. In 2020, cash operating taxes dropped dramatically to $35 million, reaching the lowest level in the five-year span.

Overall, both tax provisions and cash operating taxes peaked sharply in 2017, followed by declines in subsequent years. However, while the provision for income taxes saw a rebound in 2020, cash operating taxes continued to decline substantially. This divergence in 2020 may indicate changes in tax payment timing, tax strategy, or the recognition of deferred tax liabilities.


Invested Capital

Illumina Inc., invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Build-to-suit lease liability
Long-term debt, current portion
Long-term debt, excluding current portion
Operating lease liability1
Total reported debt & leases
Total Illumina stockholders’ equity
Net deferred tax (assets) liabilities2
Allowance for doubtful accounts3
Reserve for product warranties4
Equity equivalents5
Accumulated other comprehensive (income) loss, net of tax6
Redeemable noncontrolling interests
Noncontrolling interests
Adjusted total Illumina stockholders’ equity
Construction in progress7
Short-term investments8
Invested capital

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of allowance for doubtful accounts receivable.

4 Addition of reserve for product warranties.

5 Addition of equity equivalents to total Illumina stockholders’ equity.

6 Removal of accumulated other comprehensive income.

7 Subtraction of construction in progress.

8 Subtraction of short-term investments.


The financial data indicates several notable trends in the company's capital structure and financing components over the five-year period ending December 31, 2020.

Total reported debt & leases
This metric exhibits moderate fluctuations, beginning at $1,795 million in 2016, rising to a peak of $2,599 million in 2018, before decreasing to approximately $1,881 million in 2019 and stabilizing around $1,906 million in 2020. The increase through 2018 suggests a period of increased borrowing or lease commitments, followed by a reduction implying possible debt repayment or lease adjustments.
Total stockholders’ equity
Equity shows a consistent, steady increase year-over-year, rising from $2,197 million in 2016 to $4,694 million in 2020. The equity nearly doubled over the period, reflecting retained earnings growth, possible capital raises, or accumulated comprehensive income, indicating strengthening financial stability and increased shareholder value.
Invested capital
Invested capital generally trends upward from $2,874 million in 2016 to a peak of $4,997 million in 2019, with a slight decrease to $4,907 million in 2020. This overall growth reflects increased funding employed in the business, either through equity or liabilities, aligning with growth or expansion strategies. The small decline in 2020 suggests a minor contraction or adjustment in the capital base.

Overall, the company demonstrates a strengthening equity base coupled with management of debt levels, maintaining total invested capital at elevated levels consistent with potential expansion or operational scaling. The reduction in debt after 2018, alongside rising equity, may suggest a strategic shift towards lower leverage, improving financial flexibility.


Cost of Capital

Illumina Inc., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2019-12-29).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2018-12-30).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 35.00%) =
Operating lease liability4 ÷ = × × (1 – 35.00%) =
Total:

Based on: 10-K (reporting date: 2017-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 35.00%) =
Operating lease liability4 ÷ = × × (1 – 35.00%) =
Total:

Based on: 10-K (reporting date: 2016-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Illumina Inc., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2020 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The period between 2016 and 2020 demonstrates a fluctuating performance in economic value creation. Initially, positive economic profit is observed, which then experiences growth before culminating in a substantial loss. This is reflected in the corresponding changes in the economic spread ratio.

Economic Profit
Economic profit begins at US$28 million in 2016 and increases significantly to US$202 million in 2017. It remains positive, at US$180 million in 2018 and US$200 million in 2019, before declining sharply to a loss of US$163 million in 2020. This represents a considerable reversal in profitability.
Invested Capital
Invested capital shows a consistent upward trend throughout the period, increasing from US$2,874 million in 2016 to US$4,997 million in 2019. A slight decrease is noted in 2020, with invested capital reported at US$4,907 million. The continued growth in invested capital, despite the eventual decline in economic profit, suggests potential inefficiencies in capital allocation or a challenging operating environment in the final year.
Economic Spread Ratio
The economic spread ratio mirrors the trend in economic profit. It increases from 0.97% in 2016 to a peak of 5.63% in 2017, then gradually decreases to 4.52% in 2018 and 4.00% in 2019. A significant shift occurs in 2020, with the ratio falling to -3.31%. This negative value indicates that the company’s return on invested capital is less than its cost of capital, resulting in value destruction. The decline in the ratio from 2017 onwards, culminating in a negative value, suggests a weakening ability to generate returns exceeding the cost of funding.

The observed trends indicate a period of initial success followed by a deterioration in economic performance. While invested capital continued to grow, the company’s ability to generate economic profit diminished, ultimately leading to a loss in 2020 and a negative economic spread ratio. Further investigation would be required to determine the underlying causes of this shift.


Economic Profit Margin

Illumina Inc., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Economic profit1
Revenue
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 Economic profit. See details »

2 2020 Calculation
Economic profit margin = 100 × Economic profit ÷ Revenue
= 100 × ÷ =

3 Click competitor name to see calculations.


The economic profit exhibited substantial fluctuation between 2016 and 2020. Initially, economic profit increased significantly before declining to a negative value in the final year of the observed period. This trend is mirrored in the economic profit margin, which demonstrates a similar pattern of growth followed by a substantial decrease.

Economic Profit
Economic profit began at US$28 million in 2016 and rose dramatically to US$202 million in 2017. It remained relatively high at US$180 million in 2018 and US$200 million in 2019. However, a significant downturn occurred in 2020, resulting in an economic loss of US$163 million.
Revenue
Revenue demonstrated consistent growth from 2016 to 2019, increasing from US$2,398 million to US$3,543 million. A slight decrease in revenue was observed in 2020, with a value of US$3,239 million. While revenue generally increased, the decline in 2020 did not prevent the economic profit from becoming negative.
Economic Profit Margin
The economic profit margin increased from 1.17% in 2016 to a peak of 7.35% in 2017. It then decreased gradually to 5.41% in 2018 and 5.64% in 2019. A substantial decline was observed in 2020, with the margin falling to -5.02%. This indicates that, despite positive revenue figures, the cost of capital exceeded the economic profit generated in 2020.

The divergence between revenue growth and economic profit margin in 2020 suggests a potential increase in operational costs, a higher cost of capital, or a combination of both. Further investigation would be required to determine the underlying causes of this shift in profitability.